Home
Marksans Pharma Ltd 52 Week High

Marksans Pharma Ltd
NSE: MARKSANS
YEARHIGH
Key Highlights
- The 52 Week HIGH of Marksans Pharma Ltd is ₹ 358.5 as of 21 Feb 25 .
Company Fundamentals for Marksans Pharma Ltd
Market Price of Marksans Pharma Ltd
1M
1Y
3Y
5Y
Last Ten Days Market Price
Date | |
---|---|
21 Feb 2025 | 226.1 |
20 Feb 2025 | 232.4 |
19 Feb 2025 | 227.9 |
18 Feb 2025 | 241.05 |
17 Feb 2025 | 238.45 |
14 Feb 2025 | 230.6 |
13 Feb 2025 | 249.5 |
12 Feb 2025 | 253.8 |
11 Feb 2025 | 251.45 |
10 Feb 2025 | 267.4 |
Asset Value vs Market Value of Marksans Pharma Ltd
Market Value
₹ 0
Asset Value
₹ 0
* All values are in ₹ crores
Historical Revenue of Marksans Pharma Ltd
Revenue term means the amount of money a company earns from its primary business activities such as the sales of its products & services.\r\r\n\r\r\nTypes of Revenue:\r\r\n\r\r\n1. Operating revenue: It refers to the income generated from the core business activities, which are sales of goods or services rendered.\r\r\n\r\r\n2. Non-Operating revenue: It is the income generated from secondary sources unrelated to the primary business. Examples include rents, dividends, interest, and royalty fees.\r\r\n\r\r\nFormula for Revenue:\r\r\n\r\r\nThe formula for calculating revenue is based on two goods & services:\r\r\n\r\r\nFor goods:\r\r\nRevenue = Avg unit price x Number of Units sold\r\r\n\r\r\nFor services:\r\r\nRevenue = Avg unit price x Number of Customers served.
Historical Revenue of Marksans Pharma Ltd
Historical Net Profit of Marksans Pharma Ltd
Net profit is the amount of money a company retains after accounting for all expenses, depreciation, interest, taxes, and other deductions.\r\r\n\r\r\nNet Profit formula is expressed as:\r\r\n\r\r\nNet Profit = Total Revenue - Total Expense\r\r\n\r\r\nNet Profit Margin Ratio:\r\r\n\r\r\nNet Profit Margin Ratio = Net Profit / Total Revenue
Historical Net Profit of Marksans Pharma Ltd
Marksans Pharma Ltd News Hub
Marksans Pharma announces receipt of UKMHRA approval for Fluoxetine capsules
Marksans Pharma'announced that its wholly owned subsidiary Relonchem has received Marketing Authoriz
Read more
21 Aug 24
Marksans Pharma gets EIR from USFDA for Goa facility
The inspection has been classified as voluntary action indicated (VAI) and has been closed according
Read more
20 Aug 24
Marksans Pharma's Verna unit successfully completes USFDA inspection
Marksans Pharma announced that he USFDA has issued an Establishment Inspection Report (EIR) for its
Read more
20 Aug 24
Marksans Pharma to convene AGM
Marksans Pharma announced that the Annual General Meeting (AGM) of the company will be held on 24 Se
Read more
20 Aug 24